Subscribe
shutterstock_1524542537_michael_vi
Michael Vi / Shutterstock.com
15 February 2022MedtechAlex Baldwin

Fed Circ denies bid to reverse favourable J&J ruling

The US Court of Appeals for the Federal Circuit has affirmed two Patent Trial and Appeal Board (PTAB) rulings that a Johnson & Johnson (J&J) subsidiary’s patent is valid and infringed.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
J&J secures injunction against medical device counterfeiter
7 December 2021   Johnson & Johnson’s subsidiary Ethicon has obtained a permanent injunction against counterfeiters selling fake versions of Surgicel, an absorbable haemostat used to control bleeding during surgery.
Medtech
Fed Circuit revives bid to invalidate robotic surgery patent
3 May 2022   The US Court of Appeals for the Federal Circuit has renewed Auris Health’s attempt to invalidate Intuitive Surgical’s patent covering a robotic surgical tool.
Americas
J&J units launch prostate cancer drug suit
31 May 2022   Johnson & Johnson subsidiaries Aragon Pharmaceuticals and Janssen Biotech have sued three pharma companies for alleged infringement of five patents relating to prostate cancer treatment Erleada.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

More on this story

Americas
J&J secures injunction against medical device counterfeiter
7 December 2021   Johnson & Johnson’s subsidiary Ethicon has obtained a permanent injunction against counterfeiters selling fake versions of Surgicel, an absorbable haemostat used to control bleeding during surgery.
Americas
J&J units launch prostate cancer drug suit
31 May 2022   Johnson & Johnson subsidiaries Aragon Pharmaceuticals and Janssen Biotech have sued three pharma companies for alleged infringement of five patents relating to prostate cancer treatment Erleada.
Medtech
Fed Circuit revives bid to invalidate robotic surgery patent
3 May 2022   The US Court of Appeals for the Federal Circuit has renewed Auris Health’s attempt to invalidate Intuitive Surgical’s patent covering a robotic surgical tool.

More on this story

Americas
J&J secures injunction against medical device counterfeiter
7 December 2021   Johnson & Johnson’s subsidiary Ethicon has obtained a permanent injunction against counterfeiters selling fake versions of Surgicel, an absorbable haemostat used to control bleeding during surgery.
Americas
J&J units launch prostate cancer drug suit
31 May 2022   Johnson & Johnson subsidiaries Aragon Pharmaceuticals and Janssen Biotech have sued three pharma companies for alleged infringement of five patents relating to prostate cancer treatment Erleada.
Medtech
Fed Circuit revives bid to invalidate robotic surgery patent
3 May 2022   The US Court of Appeals for the Federal Circuit has renewed Auris Health’s attempt to invalidate Intuitive Surgical’s patent covering a robotic surgical tool.

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?